Increased Incidence of Visceral Metastases in Scottish Patients With BRCA1/2-Defective Ovarian Cancer: An Extension of the Ovarian BRCAness Phenotype
Authors:
- Charlie GourleyCGCharlie Gourley
- Caroline O. MichieCMCaroline O. Michie
- Patricia RoxburghPRPatricia Roxburgh
- Timothy A. YapTYTimothy A. Yap
- Sharon HardenSHSharon Harden
- Jim PaulJPJim Paul
- Kalpana RagupathyKRKalpana Ragupathy
- Radha ToddRTRadha Todd
- Russell PettyRPRussell Petty
- Nick ReedNRNick Reed
- Richard L. HaywardRHRichard L. Hayward
- Paul MitchellPMPaul Mitchell
- 20 May 2010
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 28 (15) , 2505-2511
Abstract
Purpose: To compare the frequency of visceral relapse of BRCA1/2-deficient ovarian cancer to that of nonhereditary controls. Patients and Methods: All patients diagnosed in Scotland with epithelial ovarian cancer (EOC) or primary peritoneal cancer (PPC) and a germline BRCA1/2 mutation were identified. Those with previous malignancy were excluded. Each remaining patient who experienced relapse was matched with two nonhereditary controls. Results: Seventy-nine patients with EOC/PPC and germline BRCA1/2 mutations were identified. Fifteen had inadequate clinical data, two had carcinosarcoma, 27 had previous breast cancer, and 16 were in remission. Of the remaining 19 patients who were BRCA1/2 deficient, 14 patients (74%) developed visceral metastases compared with six (16%) of 38 patients in the control group. The percentages of liver, lung, and splenic metastases were 53%, 32%, and 32%, respectively, in the patients compared with 5%, 3%, and 5%, respectively, in the controls. When events occurring outside the matched follow-up period were omitted, the percentages of visceral, liver, lung, and splenic metastases were 58%, 42%, 16%, and 32% in the patients compared with 5%, 0%, 0%, and 3% in controls (P < .001, P < .001, P = .066, and P = .011, respectively). In an independent validation set, the corresponding percentages of visceral, liver, lung, and splenic metastases were 63%, 46%, 13%, and 17% in the patients compared with 11%, 4%, 2%, and 2% in controls (P < .001, P < .001, P = .153, and P = .052, respectively). Conclusion: Although sporadic EOC commonly remains confined to the peritoneum, BRCA1/2-deficient ovarian cancer frequently metastasizes to viscera. These data extend the ovarian BRCAness phenotype, imply BRCA1/2-deficient ovarian cancer is biologically distinct, and suggest that patients with visceral metastases should be considered for BRCA1/2 sequencing.Keywords
This publication has 24 references indexed in Scilit:
- Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug developmentAnnals of Oncology, 2009
- Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian CancerJournal of Clinical Oncology, 2008
- Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriersEuropean Journal of Cancer, 2007
- Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinomaCancer, 2005
- Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastasesAnnals of Oncology, 2005
- One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutationsEuropean Journal of Cancer, 2004
- Improved survival in women with BRCA‐associated ovarian carcinomaCancer, 2003
- Distant metastases in ovarian carcinomaInternational Journal of Gynecological Cancer, 2003
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- The complete BRCA2 gene and mutations in chromosome 13q-linked kindredsNature Genetics, 1996